New Biosimilar Approvals for Myeloid Growth Factors and Anemia

Gary H. Lyman
Search for other papers by Gary H. Lyman in
Current site
Google Scholar
Restricted access

Biosimilars are here to stay, but whether they will enjoy widespread uptake remains to be seen. The FDA sets a high bar for approval of biosimilar products, yet many clinicians remain skeptical about the efficacy and safety of these agents. Favorable experience with >30 biosimilars in Europe provides some reassurance that these agents are safe and effective and can be substituted for the reference product.

Correspondence: Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Public Health Sciences and Clinical Research Divisions, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M3-B232, Seattle, WA 98109. Email:
  • Collapse
  • Expand
  • 1.

    US Department of Health and Human Services, Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Available at: Published April 2015. Accessed April 10, 2019.

    • Search Google Scholar
    • Export Citation
  • 2.

    Sörgel F, Schwebig A, Holzmann J, et al. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. BioDrugs 2015;29:123131.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Blackwell K, Semiglazov V, Jrasbizgib D, et al. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol 2015;26:19481953.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs 2014;28;363372.

  • 5.

    Lyman GH, Balaban E, Diaz M, et al. American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol 2018;36:12601265.

  • 6.

    Kozlowski S, Birger N, Brereton S, et al. Update of the biologic filgrastim and its biosimilar product among the Medicare population. JAMA 2018:320;929931.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 700 74 11
PDF Downloads 173 23 7
EPUB Downloads 0 0 0